In:
Blood, American Society of Hematology, Vol. 124, No. 3 ( 2014-07-17), p. 420-425
Abstract:
Increased PTK2 expression is associated with improved outcomes in patients with CLL treated with R-FC immunochemotherapy. PTK2 expression represents a useful, novel biomarker for selection of patients who will benefit from R-FC immunochemotherapy.
Type of Medium:
Online Resource
ISSN:
0006-4971
,
1528-0020
DOI:
10.1182/blood-2013-12-538975
Language:
English
Publisher:
American Society of Hematology
Publication Date:
2014
detail.hit.zdb_id:
1468538-3
detail.hit.zdb_id:
80069-7
